Neurostar RTMS denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for neurostar rtms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied NeuroStar TMS as Not FDA-Approved — and Why That Is Wrong

NeuroStar TMS received FDA 510(k) clearance for the treatment of major depressive disorder in adults and has subsequently received additional FDA clearances for other indications. A denial stating TMS is "not FDA-approved" or "not FDA-cleared" is one of the most straightforwardly rebutted denial types because the FDA's public device database provides official clearance documentation that directly contradicts the stated denial reason.

### Why This Denial Is Appealable

A factual error in the denial rationale — such as claiming a device lacks FDA clearance when it demonstrably has it — is grounds for reversal at the internal appeal stage. Under ACA Section 2719 and ERISA Section 503, UHC must conduct a full-and-fair review and consider all submitted evidence. Presenting the actual FDA 510(k) clearance record directly contradicts the stated denial reason. If the internal appeal is denied despite this evidence, independent external review is available and the external reviewer will evaluate the same evidence free of any relationship with UHC.

### Your Appeal Timeline

• Internal appeal: File immediately — deadlines are printed on your denial letter, commonly 180 days from the denial. Pre-service appeals must be decided within 30 days; post-service within 60 days.
• External review: If the internal appeal is adverse, request independent external review within four months of that decision. The external reviewer's determination is binding on UHC.
• Expedited option: If urgent, request expedited processing — decisions are required within 72 hours.

### Documentation to Gather

1. FDA clearance documentation — download the official 510(k) clearance summary for NeuroStar TMS directly from the FDA's publicly accessible 510(k) database (search "NeuroStar" or the specific K-number). Print and attach it to your appeal as Exhibit A. 2. Diagnosis confirmation — psychiatric records confirming your diagnosis falls within the FDA-cleared indication for the device. 3. Prescriber letter — a letter from your psychiatrist confirming the device is being used for an FDA-cleared indication and that the treatment is medically necessary for your condition. 4. Prior-treatment history — documentation of prior treatments and their outcomes, supporting the broader medical-necessity context.

### Criteria-Mapping Structure

State the denial reason verbatim. Then, directly below, reproduce the FDA clearance information (510(k) number, cleared indication, clearance date) and attach the FDA document as an exhibit. Request UHC's published coverage policy for TMS and verify whether the policy itself references FDA clearance as a coverage requirement — if so, the clearance document satisfies that requirement on its face. If UHC's policy also requires additional clinical criteria, complete a full criteria-mapping table addressing each requirement with chart-based evidence as described in the medical-necessity guidance above.